VIVUS Inc. (VVUS)

4.33
0.02 0.46
NASDAQ : Health Technology
Prev Close 4.31
Open 4.32
Day Low/High 4.23 / 4.38
52 Wk Low/High 2.15 / 6.41
Volume 221.01K
Avg Volume 101.70K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 43.85M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Update on a Holding

Thus far, there have been no surprises during this pharmaceutical company's discussions with the FDA about one of its products.

Vivus' FDA Advisory Panel: Live Blog Recap

Vivus' FDA Advisory Panel: Live Blog Recap

Here's our live coverage of the FDA review of Vivus's weight-loss drug, Qnexa.

Vivus: Prepping for Thursday's FDA Panel

Question and thoughts about the FDA's upcoming advisory panel to review Vivus' weight-loss drug.

Street Elite Get Early Crack at Arena Study

Street Elite Get Early Crack at Arena Study

Analysts are free to disclose NEJM studies about Arena weight-loss drug while media remains under embargo.

Intel: Analysts' Upgrades, Downgrades

Intel: Analysts' Upgrades, Downgrades

Intel price target higher at Citi and estimates are higher at Barclays and UBS.

Business Highlights

Business Highlights

Business Highlights

Citigroup, MBIA, Apple Among Big Movers

Citigroup, MBIA, Apple, Brooks Automation among big market movers Tuesday

Drug Approval Looks Promising

The FDA report says this name's weight-loss treatment is effective but the agency does have some questions about its safety.

Vivus Weight-Loss Pill Works - FDA

The FDA posted a review of Vivus' Qnexa ahead of Thursday's advisory panel meeting.

FDA To Review First Of 3 New Weight Loss Drugs

FDA to evaluate obesity drug that would be the first new prescription treatment in a decade

Stocks Under $10 Weekly Summary

It was a quiet week for the model portfolio holdings, but we watched our names closely as the market headed back up.

Biotech Stock Mailbag: Somaxon

Biotech Stock Mailbag: Somaxon

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Update on a Holding

Shares of this biopharmaceutical company are trading higher this morning on recent good news for one of its products.

Stocks Under $10 Weekly Summary

As the calendar turned the page into the third quarter this week, we added shares to three model portfolio names.

Arena Gets Small Dowry for Obesity Drug

Arena Gets Small Dowry for Obesity Drug

Arena's partnership with Eisai for its obesity drug is a win, but the terms are less than generous.

Stocks Under $10 Weekly Summary

We added shares to a model portfolio holding on Friday, at the end of a week that painted a mixed economic picture.

Stocks Under $10 Weekly Summary

Despite mixed economic news and quadruple-witching options expiration, it was a fairly quiet week for the model portfolio.

Biotech Stock Mailbag: Spectrum Pharma

Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.

Wall Street Confidential Podcast: 6/15/10

Jim Cramer discusses today's market action

Biotech Stock Mailbag Readers' Portfolio: Update

The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 11% this year.

Stocks Under $10 Weekly Summary

During another week of roller coaster trading, we added shares to three model portfolio names and raised one rating.

Stocks Under $10 Weekly Summary

During a volatile trading week marked by mixed economic data, we added shares to one model portfolio holding.

Real or Imagined?

Market players are convinced the jobs number will be bullish, but it's hard to know how things will shake out, given data skewed by census jobs and hiring related to the oil spill.

Healthy Leads

Two of our health care names are trading higher today based on strong products and likely improving margins.

Stocks Under $10 Weekly Summary

While riding the waves of market volatility, we added shares to two model portfolio holdings this week.

Stocks Under $10 Weekly Summary

We added a new name to the model portfolio, expanded four holdings and raised one rating during this volatile week.

Reviewing Potential Opportunities

We are looking at five model portfolio names and offering a roadmap for what could be a volatile trading session.

Stocks Under $10 Weekly Summary

This week, we added to our stake in a model portfolio energy holding and booked some profits from two other names.

Booking Profits in a Strong Market

This holding is trading 54% above our cost basis -- it's prudent to take some off the table here. Also, lowering our rating.

Stocks Under $10 Weekly Summary

During a volatile and busy week, we made several adjustments to the model portfolio, including adding a new position.

TheStreet Quant Rating: D (Sell)